Inclusion Body Myositis Research

Inflammatory cells invading muscle tissues are one characteristic of inclusion body myositis, but the disease is different from other inflammatory myopathies in that muscle degeneration also occurs. Inclusion body myositis is named for the clumps of redundant cellular material the "bodies" that collect in the muscle tissues.

There are some genetic forms of inclusion body myositis in which, for the most part, inflammation is not a main part of the IBM. For this reason, these forms are often called inclusion body myopathy, leaving out the “itis” in the disease name to reflect the relation lack of inflammation.

Inclusion body myositis is mostly a disease of men, but women also can be affected. Its beginning is normally after age 50 and progression is slow. Currently there are no medications for Inclusion Body Myopathy Treatment, but the disease is not considered life-threatening. Most people with IBM remain able to walk, though they may require a cane or wheelchair for long period.

New research is quickly leading to increased understanding of inclusion body myositis. Scientists are examining factors that may trigger the disease such as viruses, certain medication or vaccines. All these factors are being studied so inflammatory myopathies like Inclusion body myositis can someday be better understood, treated or possibly prevented entirely.